RESULTS	The risk of relapse was 2.8 times higher for placebo-treated patients than for escitalopram-treated patients ( p < .001 ) , resulting in significantly fewer escitalopram-treated patients relapsing ( 22 % vs. 50 % ) , at both doses .\